Hello Traders & Readers,
The alert that you’ve been waiting patiently for is finally here and it’s time to reveal it for the selected few that have an interest in strong potential “momentum” plays.
That potential huge momentum pick is: CHHE
CHHE (China Health Industries Holdings, Inc.) – Current PPS. - $.025
CHHE is a pure momentum play with a VERY THIN level two. It could have huge upside of a possible triple to quadruple digit percentage gainer.
CHHE is a holdings company that has more offerings than a Chinese buffet line.
The list of information and avenues that CHHE explore and develop is like a rabbit hole of non-stop information and potential.
Plays like CHHE are the unique plays that surface every so often, like lunar eclipses, or like the rebirths of North American cicadas.
Without boring you with anymore introductions to this slice of potential happiness, let me take right to the center of what makes CHHE our prized trophy play.
BUSINESS SUMMARY
(CHHE - China Health Industries Holdings, Inc.)
Current PPS - $.025
China Health Industries Holdings, Inc., through its subsidiaries, engages in the manufacture and sale of health products, and green or organic food; and detection of disease susceptibility or pre-disposition through genetic studies primarily in the People’s Republic of China.
It provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin C for freckle removal and supplementing the water content of the skin; propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root; capsules and tablets for removing acne, relieving eyestrain, increasing bone density, improving memory and nutritional anemia, relaxing bowels and promoting the discharge of lead, increasing immunity and relieving physical fatigue, and dispelling chloasma; and multivitamin, mineral, and iron supplements.
The company also offers health and organic green food products, such as abalone, sea cucumber, and frog oil soft capsules; ganodermalucidum and aweto soft capsules; propolis soft capsules; deep sea fish oil; liquid calcium; soybean isoflavone; royal jelly; and sleeping beauty, virility max, ruddy, blood cleanser soft, and colon cleanser capsules, as well as energy elemental power. In addition, it provides medical drugs that are used for treating urinary tract infection; bacterial infection of the intestines; fever caused hyperpyrexia and headaches; bronchial asthma; cough and reduction of sputum; cough and excessive phlegm; clear lungs; phlegm and relieving cough in children; neurastheria, dizziness, and insomnia; fatigue and acratia; digestive tract cancer; uterine bleeding brought on by menopause; stomach pain, brash, and acid reflux; and anorexia, gastric hypersecretion, and dyspepsia.
The company sells its products through sales agents. China Health Industries Holdings, Inc. is based in Harbin City, the People’s Republic of China.
MARKET OUTLOOK
The global health care industry is going through a period
of “glocalization,” a term that combines the words “globalization” and “localization” to describe the adaptation of global products or services to accommodate the needs of people in a specific locale.
Typically associated with efforts by large consumer companies to boost sales by tailoring their products and menus to appeal to local tastes, glocalization also applies to health care: Industry issues are global, even if care is usually delivered locally. And while the effects of these issues are influenced by local factors, many challenges are shared around the world to varying degrees, as are the opportunities to innovate to solve them.
Total global health spending was expected to rise by 2.6 percent in 2013 before accelerating to an average of 5.3 percent a year over the next four years (2014-2017).
This growth will place enormous pressure on governments, health care delivery systems, insurers, and consumers in both developed and emerging markets to deal with issues such as an aging population, the rising prevalence of numerous chronic diseases, soaring costs, uneven quality, imbalanced access to care due to workforce shortages, infrastructure limitations and patient locations, and disruptive technologies.
Across the globe there have never been more health care challenges than there are today. However, these challenges can push stakeholders to innovate in new and exciting ways and to generate scientific, medical, and care delivery breakthroughs that can improve the health of people worldwide. This 2014 global health care outlook examines the current state of the sector, describes the top issues facing stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for 2014 and beyond.
(The above is the healthcare industry according to www2.deloitte.com)
There you have it.
Not to sound like a broken record but the potential for this momentum rocket play could be perfectly aligned and ready for embarkation into orbit.
Be sure to do your own due diligence in addition to anything you’ve read here. 
